查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971755

治疗诊断学市场分析及预测（至2035年）：依类型、产品类型、服务、技术、组件、应用、最终使用者、设备、流程划分

Theranostics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Device, Process
出版日期: | 出版商: Global Insight Services | 英文 397 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，治疗诊断学市场规模将从2024年的36亿美元成长至118亿美元，复合年增长率约为12.6%。治疗诊断学市场将治疗和诊断功能整合到单一平台，从而实现个人化治疗策略。这种创新方法将标靶治疗与诊断影像或生物标记相结合，以提高治疗效果并监测治疗反应。在分子成像、奈米技术和生物标记发现等领域取得进展的推动下，随着精准医疗的日益普及，治疗诊断学市场预计将迎来显着增长。癌症发病率的上升和对个人化医疗解决方案需求的增长进一步推动了市场发展，为製药和诊断行业的相关人员创造了巨大的成长机会。

预计治疗诊断学市场将迎来显着成长，主要驱动力是诊断和治疗在个人化医疗中的融合。放射性药物是市场领导者，其中放射性同位素和放射性标记肽在增强标靶癌症治疗方面发挥关键作用。紧随其后的是影像学领域，包括PET和SPECT技术，这进一步证实了它们在精准疾病诊断中的重要性。由于癌症发病率的上升以及对标靶治疗的需求，肿瘤学细分市场预计将呈现最高的成长率。心血管治疗诊断是第二大成长领域，这主要得益于心臟影像造影剂技术的进步。製药公司和诊断设备製造商之间日益密切的合作正在加速该领域的创新。此外，人工智慧与影像和诊断技术的融合正在提高治疗诊断解决方案的准确性和效率。随着患者和医疗服务提供者寻求更安全、更有效的治疗方法，对微创手术的需求也进一步推动了市场成长。

市场区隔
类型 显影剂、治疗剂、放射性同位素、生物标记、奈米颗粒、小分子、抗体、胜肽、基因治疗
产品 试剂盒、试剂、仪器、软体、耗材、检测系统、诊断设备、治疗设备
服务 咨询、维护、安装、培训、数据分析、远端监控
科技 聚合酶次世代定序（NGS）、免疫检测分析、质谱分析、微阵列、流式细胞技术、液态生物检体
成分 硬体、软体和服务
应用领域 肿瘤科、神经科、心臟科、感染疾病、内分泌科、消化科、肺科
最终用户 医院、诊断检查室、研究实验室、製药公司、生技公司、学术机构
装置 PET扫描仪、MRI扫描仪、CT扫描仪、超音波设备、伽马摄影机
过程 体内、试管内

市场概况：

受创新定价策略和新产品涌现的推动，治疗诊断学市场正经历市场份额的动态变化。主要企业正利用先进技术，并透过具竞争力的定价来提升产品的可及性和普及度。不断涌入市场的新产品反映了强大的开发平臺，旨在满足日益增长的个人化医疗需求。这一趋势支持了该行业整合治疗和诊断能力，并使其在精准医疗领域占据领先地位的努力。竞争基准分析表明，策略联盟和併购正在推动竞争优势的形成。监管影响至关重要，严格的指导方针规范市场准入和产品开发。儘管市场由少数几家主要企业主导，但新兴企业也在创新和策略联盟的推动下取得了显着进展。北美和欧洲的法规结构尤其具有影响力，塑造市场动态，并创造了有利于成长的竞争环境。随着技术进步和监管支持为持续扩张铺平道路，该市场的未来前景光明。

主要趋势和驱动因素：

治疗诊断学市场正经历强劲成长，这主要得益于个人化医疗和标靶治疗的进步。诊断和治疗功能的整合是关键趋势，能够提高治疗的精确度和有效性。随着医疗系统致力于提供更个人化的患者照护，这种方法正日益受到重视。癌症和心血管疾病等慢性病的日益增加也是推动这一增长的重要因素。这些疾病需要创新的治疗方案，进一步促进了治疗诊断学的应用。此外，影像技术的进步提高了诊断的准确性，从而能够更早发现和早期疗育。伴随诊断的兴起也是一个显着趋势，有助于制定个人化的治疗方案。治疗诊断学产品监管核准的不断增加反映出人们对其潜力的信心日益增强。随着新兴市场医疗基础设施的完善和对先进疗法需求的成长，这些市场正迎来盈利的机会。投资研发的企业有望抓住这些不断扩大的机会，并在不断发展的治疗诊断学领域确立领先地位。

限制与挑战：

治疗诊断学市场面临许多显着的限制与挑战。其中一个主要挑战是整合诊断和治疗技术所带来的高昂成本，这给医疗服务提供者和患者都带来了沉重的经济负担。这种经济壁垒限制了诊疗一体化技术的普及和广泛应用，尤其是在新兴市场。监管的复杂性也是一项重大挑战。治疗诊断学产品需要遵守复杂的核准流程，这会延迟其市场准入并增加研发成本。此外，缺乏跨区域的标准化法规结构进一步阻碍了全球市场的扩张。另一个挑战是医疗专业人员对治疗诊断学的认知和理解不足。这种知识差距可能会阻碍这些技术在临床环境中的有效应用，并限制其潜在益处。此外，该领域技术的快速发展需要持续的研发投入。这种需求迫使企业在保持财务永续性的同时不断创新。最后，治疗诊断学应用中与病患资讯相关的资料隐私问题构成了一项重大障碍。确保强有力的资料保护措施对于赢得病患信任和遵守监管规定至关重要。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 影像剂
    • 治疗剂
    • 放射性同位素
    • 生物标誌物
    • 奈米颗粒
    • 低分子化合物
    • 抗体
    • 胜肽
    • 基因治疗
  • 市场规模及预测：依产品划分
    • 成套工具
    • 试剂
    • 装置
    • 软体
    • 消耗品
    • 检测系统
    • 诊断设备
    • 治疗设备
  • 市场规模及预测：依服务划分
    • 咨询
    • 维护管理
    • 安装
    • 训练
    • 数据分析
    • 远端监控
  • 市场规模及预测：依技术划分
    • PCR
    • 次世代定序（NGS）
    • 免疫检测
    • 质谱分析
    • 微阵列
    • 流式细胞技术
    • 液态生物检体
  • 市场规模及预测：依组件划分
    • 硬体
    • 软体
    • 服务
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 神经病学
    • 心臟病学
    • 感染疾病
    • 内分泌学
    • 胃肠病学
    • 呼吸系统
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断检查室
    • 研究所
    • 製药公司
    • 生技公司
    • 学术机构
  • 市场规模及预测：依设备划分
    • PET扫描仪
    • 核磁共振扫描仪
    • CT扫描仪
    • 超音波设备
    • 伽马摄影机
  • 市场规模及预测：依製程划分
    • In vivo
    • 体外

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Advanced Accelerator Applications
  • Theragnostics
  • Lantheus Holdings
  • NanoMab Technology
  • Radiomedix
  • Telix Pharmaceuticals
  • Blue Earth Diagnostics
  • Isotopia Molecular Imaging
  • Sofie Biosciences
  • Endocyte
  • Navidea Biopharmaceuticals
  • Cyclopharm
  • ImaginAb
  • OncoNano Medicine
  • Cerveau Technologies

第九章：关于我们

简介目录
Product Code: GIS34343

Theranostics Market is anticipated to expand from $3.6 billion in 2024 to $11.8 billion by 2034, growing at a CAGR of approximately 12.6%. The Theranostics Market encompasses the integration of therapeutic and diagnostic capabilities within a single platform, enabling personalized treatment strategies. This innovative approach combines targeted therapies with diagnostic imaging or biomarkers to enhance treatment efficacy and monitor therapeutic responses. As precision medicine gains traction, theranostics is poised for significant growth, driven by advancements in molecular imaging, nanotechnology, and biomarker discovery. The market is further propelled by increasing cancer prevalence and the demand for tailored healthcare solutions, promising substantial opportunities for stakeholders in the pharmaceutical and diagnostic sectors.

The Theranostics Market is poised for substantial growth, primarily driven by the integration of diagnostics and therapeutics in personalized medicine. Radiopharmaceuticals lead the market, with radioisotopes and radiolabeled peptides being pivotal in enhancing targeted cancer treatment. The imaging segment, comprising PET and SPECT technologies, follows closely, underscoring their importance in precise disease diagnosis. The oncology sub-segment is the top performer, driven by the rising prevalence of cancer and the need for targeted therapies. Cardiovascular theranostics, as the second highest performing sub-segment, is gaining momentum due to advancements in imaging agents for heart disease. Increasing collaboration between pharmaceutical companies and diagnostic firms is accelerating innovation in this field. Additionally, the integration of artificial intelligence in imaging and diagnostics is enhancing the accuracy and efficiency of theranostic solutions. The demand for minimally invasive procedures is further propelling market growth, as patients and healthcare providers seek safer and more effective treatment options.

Market Segmentation
TypeImaging Agents, Therapeutic Agents, Radioisotopes, Biomarkers, Nanoparticles, Small Molecules, Antibodies, Peptides, Gene Therapy
ProductKits, Reagents, Instruments, Software, Consumables, Assay Systems, Diagnostic Devices, Therapeutic Devices
ServicesConsultation, Maintenance, Installation, Training, Data Analysis, Remote Monitoring
TechnologyPCR, NGS, Immunoassays, Mass Spectrometry, Microarrays, Flow Cytometry, Liquid Biopsies
ComponentHardware, Software, Services
ApplicationOncology, Neurology, Cardiology, Infectious Diseases, Endocrinology, Gastroenterology, Respiratory
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Academic Institutions
DevicePET Scanners, MRI Scanners, CT Scanners, Ultrasound Devices, Gamma Cameras
ProcessIn Vivo, In Vitro

Market Snapshot:

The Theranostics market is witnessing a dynamic shift in market share, driven by innovative pricing strategies and a surge in new product launches. Key industry players are leveraging advanced technologies to offer competitive pricing, enhancing accessibility and adoption. The market is characterized by a continuous influx of novel products, reflecting a robust pipeline of developments aimed at meeting the growing demand for personalized medicine. This trend underscores the industry's commitment to integrating therapeutic and diagnostic capabilities, positioning itself at the forefront of precision healthcare. Competition benchmarking reveals a landscape marked by strategic alliances and mergers, enhancing competitive advantage. Regulatory influences are pivotal, with stringent guidelines shaping market entry and product development. The landscape is dominated by a few key players, yet emerging companies are making significant inroads, driven by innovation and strategic partnerships. Regulatory frameworks in North America and Europe are particularly influential, dictating market dynamics and fostering a competitive environment ripe for growth. The market's future is promising, with technological advancements and regulatory support paving the way for continued expansion.

Geographical Overview:

The theranostics market is witnessing notable expansion across various regions, each exhibiting unique growth dynamics. North America is at the forefront, driven by advanced healthcare infrastructure and significant investments in personalized medicine. The region's focus on integrating diagnostics and therapeutics enhances its market leadership. Europe follows closely, with strong regulatory support and a growing emphasis on precision medicine fostering a conducive environment for theranostics. Asia Pacific is rapidly emerging as a lucrative market, propelled by substantial investments in healthcare and technological advancements. Countries like China and India are spearheading growth, driven by increasing healthcare expenditures and a rising demand for personalized treatment solutions. Latin America and the Middle East & Africa are also showing promising growth potential. In Latin America, improving healthcare infrastructure and rising awareness of personalized medicine are key drivers. Meanwhile, the Middle East & Africa are recognizing the value of theranostics in addressing regional healthcare challenges and improving patient outcomes.

Key Trends and Drivers:

The theranostics market is experiencing robust growth, propelled by advancements in personalized medicine and targeted therapies. A key trend is the integration of diagnostic and therapeutic capabilities, which enhances treatment precision and efficacy. This approach is gaining traction as healthcare systems aim to provide more tailored patient care. Increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, is a significant driver. These conditions necessitate innovative treatment solutions, further fueling theranostics adoption. Additionally, advancements in imaging technologies are enhancing diagnostic accuracy, enabling early detection and intervention. The rise of companion diagnostics is another notable trend, supporting the development of personalized treatment regimens. Regulatory bodies are increasingly approving theranostic products, reflecting growing confidence in their potential. Emerging markets present lucrative opportunities as healthcare infrastructure improves and demand for advanced treatments rises. Companies investing in research and development are poised to capitalize on these expanding opportunities, positioning themselves as leaders in the evolving theranostics landscape.

Restraints and Challenges:

The Theranostics Market encounters several notable restraints and challenges. A primary challenge is the substantial cost associated with integrating diagnostic and therapeutic technologies, which imposes financial burdens on healthcare providers and patients alike. This financial barrier limits accessibility and adoption, particularly in emerging markets. Regulatory complexities also pose significant challenges. Navigating the intricate approval processes for theranostic products can delay market entry and increase development costs. Moreover, the lack of standardized regulatory frameworks across different regions further complicates global market expansion. Another challenge is the limited awareness and understanding of theranostics among healthcare professionals. This knowledge gap can impede the effective implementation of these technologies in clinical settings, restricting their potential benefits. Additionally, the rapid pace of technological advancements in the field requires continuous investment in research and development. This necessity places pressure on companies to innovate while managing financial sustainability. Lastly, data privacy concerns related to patient information in theranostic applications present a significant hurdle. Ensuring robust data protection measures is crucial to gaining patient trust and regulatory compliance.

Key Players:

Advanced Accelerator Applications, Theragnostics, Lantheus Holdings, NanoMab Technology, Radiomedix, Telix Pharmaceuticals, Blue Earth Diagnostics, Isotopia Molecular Imaging, Sofie Biosciences, Endocyte, Navidea Biopharmaceuticals, Cyclopharm, ImaginAb, OncoNano Medicine, Cerveau Technologies

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Imaging Agents
    • 4.1.2 Therapeutic Agents
    • 4.1.3 Radioisotopes
    • 4.1.4 Biomarkers
    • 4.1.5 Nanoparticles
    • 4.1.6 Small Molecules
    • 4.1.7 Antibodies
    • 4.1.8 Peptides
    • 4.1.9 Gene Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Kits
    • 4.2.2 Reagents
    • 4.2.3 Instruments
    • 4.2.4 Software
    • 4.2.5 Consumables
    • 4.2.6 Assay Systems
    • 4.2.7 Diagnostic Devices
    • 4.2.8 Therapeutic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation
    • 4.3.2 Maintenance
    • 4.3.3 Installation
    • 4.3.4 Training
    • 4.3.5 Data Analysis
    • 4.3.6 Remote Monitoring
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PCR
    • 4.4.2 NGS
    • 4.4.3 Immunoassays
    • 4.4.4 Mass Spectrometry
    • 4.4.5 Microarrays
    • 4.4.6 Flow Cytometry
    • 4.4.7 Liquid Biopsies
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Neurology
    • 4.6.3 Cardiology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Endocrinology
    • 4.6.6 Gastroenterology
    • 4.6.7 Respiratory
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Diagnostic Laboratories
    • 4.7.3 Research Institutes
    • 4.7.4 Pharmaceutical Companies
    • 4.7.5 Biotechnology Companies
    • 4.7.6 Academic Institutions
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 PET Scanners
    • 4.8.2 MRI Scanners
    • 4.8.3 CT Scanners
    • 4.8.4 Ultrasound Devices
    • 4.8.5 Gamma Cameras
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 In Vivo
    • 4.9.2 In Vitro

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Device
      • 5.2.1.9 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Device
      • 5.2.2.9 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Device
      • 5.2.3.9 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Device
      • 5.3.1.9 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Device
      • 5.3.2.9 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Device
      • 5.3.3.9 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Device
      • 5.4.1.9 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Device
      • 5.4.2.9 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Device
      • 5.4.3.9 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Device
      • 5.4.4.9 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Device
      • 5.4.5.9 Process
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Device
      • 5.4.6.9 Process
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Device
      • 5.4.7.9 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Device
      • 5.5.1.9 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Device
      • 5.5.2.9 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Device
      • 5.5.3.9 Process
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Device
      • 5.5.4.9 Process
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Device
      • 5.5.5.9 Process
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Device
      • 5.5.6.9 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Device
      • 5.6.1.9 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Device
      • 5.6.2.9 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Device
      • 5.6.3.9 Process
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Device
      • 5.6.4.9 Process
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Device
      • 5.6.5.9 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Theragnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Lantheus Holdings
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 NanoMab Technology
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Radiomedix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Telix Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Blue Earth Diagnostics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Isotopia Molecular Imaging
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sofie Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Endocyte
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Navidea Biopharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cyclopharm
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 ImaginAb
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 OncoNano Medicine
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cerveau Technologies
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us